Posted by Michael Wonder on 21 Jun 2019
U.S. group says Novartis MS drug price out of line with benefit
21 June 2019 - A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new multiple sclerosis drug Mayzent, calling its $88,561 list price “far out of line” compared with its benefits for patients.
The Boston-based Institute for Clinical and Economic Review, which has been reviewing Mayzent for months, recommended that Novartis lower the drug’s price.
Mayzent was approved in March by the U.S. FDA for adults with relapsing forms of multiple sclerosis, including active secondary progressive disease.
